PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF PURCHASE OPTION TIED TO SERIES B CONVERTIBLE PREFERRED STOCK OFFERING

Core Viewpoint - PetVivo Holdings, Inc. has successfully completed a $5 million equity financing, which will support the commercialization of its innovative veterinary medical products, including SPRYNG and PrecisePRP [1][4] Group 1: Financing Details - The company received $1 million from the full exercise of the remaining shares in a purchase option, completing the total offering of $5 million [1] - The purchase price for one share of Series B Convertible Preferred Stock was set at $1, with a conversion rate of one share for one common stock [1] - Prior to this exercise, the company had already received $4 million from the offering [1] Group 2: Product Information - SPRYNG is an intra-articular injectable device that utilizes OsteoCushion Technology, designed to manage joint pain and improve joint mechanics in animals [2][7] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product that provides a consistent dose of 4 billion platelets per vial, designed for easy use by veterinarians without the need for blood draws [3][7] Group 3: Company Overview - PetVivo Holdings focuses on the manufacturing and commercialization of innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [6] - The company holds a portfolio of 21 patents protecting its biomaterials and products, indicating a strong intellectual property position [7]